2′‐chlorodeoxyadenosine (2‐CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH‐S‐98 protocol of the histiocyte society
- 3 September 2009
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 53 (7) , 1271-1276
- https://doi.org/10.1002/pbc.22229
Abstract
Background: A prospective phase II Histiocyte Society study, LCH‐S‐98, evaluated the efficacy of 2‐chlorodeoxyadenosine (2‐CdA) monotherapy as salvage therapy in Langerhans cell histiocytosis (LCH).Procedures: Patients with poor and intermediate risk LCH not responsive to initial therapy and patients with low‐risk chronic recurrent LCH were evaluated for response and survival after treatment with 2–6 courses of 2‐CdA.Results: Forty‐six patients (55%) had involvement of risk organs; lung, liver, spleen, or hematopoetic system (RO+), 37 (45%) were RO−. Twenty‐two percent of RO+ patients had a good response while 44% progressed, 62% RO− patients responded, and 11% progressed. Two‐year predicted survival is 48% for RO+, 97% for RO− patients, 100% for RO+ patients reactivating in non‐risk organs, 67% for RO− patients reactivating in risk organs. Two‐year pSU for the entire group is 68%. Seventy‐three percent of patients with a poor response to 2‐CdA died. Sixty‐five percent patients >2 years old and 30% <2 years old survived. There was a median of 26 months from diagnosis to 2‐CdA for responders compared to a median of 5 months for non‐responders. Twenty‐one percent of patients treated 12 months from diagnosis responded.Conclusion: 2‐CdA is active in LCH. It produces a higher response rate in patients with low‐risk multisystem or multifocal bone disease than those with risk organ involvement. “Risk” patients who fail to respond to 2‐CdA have a high mortality. Patient age at 2‐CdA therapy and length of time from diagnosis to 2‐CdA significantly affect response and survival. Pediatr Blood Cancer 2009; 53:1271–1276.Keywords
Funding Information
- Histiocytosis Association of America
- Histiocytosis Association of Canada
This publication has 28 references indexed in Scilit:
- Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunctionEuropean Journal Of Cancer, 2005
- Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society—Late Effects Study GroupPediatric Blood & Cancer, 2004
- Successful treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosineRespirology, 2003
- Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemiaThe Hematology Journal, 2002
- Response to initial treatment of multisystem langerhans cell histiocytosis: An important prognostic indicatorMedical and Pediatric Oncology, 2002
- Treatment of Multisystem Langerhans Cell Histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 StudiesKlinische Padiatrie, 2000
- Delayed Onset of Autoimmune Hemolytic Anemia Complicating Cladribine Therapy for Waldenström MacroglobulinemiaLeukemia & Lymphoma, 2000
- Epstein–Barr Virus–Associated Lymphoma after Treatment of Macroglobulinemia with CladribineNew England Journal of Medicine, 1999
- A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group.Archives of Disease in Childhood, 1996
- LCH‐I: A randomized trial of etoposide vs. vinblastine in disseminated langerhans cell histiocytosisMedical and Pediatric Oncology, 1994